

# The Canadian HTA Landscape (2020–2023): A Comparative Study Of CDA-AMC And INESSS Recommendations

HTA64




Sola-Barrado B.<sup>1</sup>, Cervelo-Bouzo, P.<sup>1</sup>, Wang T.<sup>1</sup>, and McAuslane N.<sup>1</sup>

Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom.




## INTRODUCTION

Health technology assessment (HTA) informs reimbursement decisions in **Canada**. Two agencies conduct HTA separately: Canada's Drug Agency (**CDA-AMC**), which evaluates medicines for all provinces and territories except Quebec, and Quebec's Institut National d'Excellence en Santé et en Services Sociaux (**INESSS**), which serves Quebec.



## OBJECTIVES

To compare HTA **timelines** and **outcomes** for new active substances (NASs) evaluated by CDA-AMC and INESSS between 2020 and 2023, focusing on common compounds assessed by both agencies.



## METHODS

**Data:** 1<sup>st</sup> HTA reports from CDA-AMC and INESSS (01-01-2020 to 31-12-2023).

**Common compounds:** NASs reviewed by both agencies.

**Submission sequence:**

- Parallel: submission to HTA before Notice of Compliance (**Pre-NOC**).
- Sequential: submission to HTA after NOC (**Post-NOC**).


**Time measures:**

- Time to submission = Health Canada (HC) approval → HTA submission.
- Time to recommendation = HC approval → HTA recommendation.
- Submission gap = Submission INESSS – Submission CDA-AMC.

**Statistical analysis:** Wilcoxon rank sum test for differences in timelines.

**Recommendation classification:**

- Optimal: reimburse or reimburse with conditions.
- Non-optimal: do not reimburse.



## RESULTS

➤ NASs reviewed between 2020 and 2023:

- CDA-AMC: 112 & INESSS: 103
- Common compounds: 97
- Oncology products: 52.6% (51/97)

➤ HTA recommendations (**Figure 1**):

- CDA-AMC: 79.4% (77/97) optimal
- INESSS: 64.9% (63/97) optimal

➤ Submission trends:

- Pre-NOC - Parallel submissions:
  - CDA-AMC: 53.6% (52/97)
  - INESSS: 52.6% (51/97)

➤ Time to submission (**Figure 2.A**):

- CDA-AMC: 47 days before HC approval
- INESSS: 14 days before HC approval (p = 0.209)

➤ Time to recommendation (**Figure 2.B**):

- CDA-AMC 244 days, INESSS 283 days (p = 0.749)

➤ Submission sequence: 89.7% (87/97) first submitted to CDA-AMC

- Of these: 58.6% (51/87) within 1 month, 32.2% (28/87) within 1–3 months submitted to INESSS (**Figure 3**)

Figure 1. 1st HTA Recommendation for Common Compounds in Canada (2020–2023)




Figure 2. Time from Health Canada Approval to HTA Submission and Recommendation in Canada (2020–2023)





Figure 3. Submission Gap Between CDA-AMC and INESSS (2020–2023)



## CONCLUSIONS

- Timelines from HC approval to HTA submission and recommendation were comparable between CDA-AMC and INESSS, with no significant differences observed (p > 0.05).
- Most NASs were first submitted to CDA-AMC, with INESSS generally following within three months.
- Overall, the findings suggest broadly similar company submission strategies across Canadian jurisdictions.

## CONTACT INFORMATION



[bsola@cirs-ci.org](mailto:bsola@cirs-ci.org). Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom.

